December 1, 2023 /

AGAMREE® Approval with Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals joined PPMD for a community webinar on Wednesday, November 15th at 1:00 PM ET to discuss AGAMREE® (vamorolone) oral suspension, a new FDA-approved novel corticosteroid indicated for individuals age 2 years and older diagnosed with Duchenne muscular dystrophy. Catalyst Pharmaceuticals, the drug company commercializing AGAMREE in the US, provided an overview of the drug, its approved label, and its patient services program supporting AGAMREE.

AGAMREE® is a registered trademark of Santhera Pharmaceuticals (Schweiz) AG.

Posted on December 1, 2023

Join Our Mailing List